GLG News by Physicians who Treat ADHD (US)

The Stark bill aims to offer both incentives and eventually financial penalties to speed the adoption of electronic medical records. It includes provisions that would create a "standard", however it is unclear the degree of interoperability different systems would have, and the degree to which the interfaces...

This is hardly news to any practicing psychiatrist. It has become a profession devoid of any meaning. The quality of treatment has deteriorated beyond belief. 

Unfortunately, many insurance payors do not realize that allowing psychotherapy visits may save the money in the long run by reducing the need for much more costly Inpatient psychiatric treatment. I find that my patients who receive psychotherapy are much less likely to miss work and much...

This large study shows that PD patients' severity of motor dysfunction is better on rasagiline than on placebo.

If truly an association, this will alter the use of this drug.

All is not as it seems when reported in the press, especially the non-scientific press.

DDP4 inhibitor class fairly new.  Another arrow in the theraputic quiver

“Personalized medical diagnositics” looks to be evolving as a high impact area in neuropsychiatric drug development.  Such ‘genetic biomarker’ platforms, based on either pharmacogenetic profiles coming from DNA blueprints or gene products from a simple blood draw, aim to identify patients who are...

Patients may ask about this.  Haven't heard anyone yet.

‘One drug, many uses’ can make lots of sense clinically and commercially.   Seeking additional FDA indications for a specific drug has obvious business benefits:  greater revenue stream, improved branding, potentially longer market exclusivity, greater franchising potential of the drug...